Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068247 | 1.00 | CRBN (0.35) | CRBNDDB1CD274PDCD1LG2IDO1 | |
| SCHEMBL29348600 | 0.87 | PDCD1LG2 (0.37) | CRBNDDB1CD274PDCD1LG2ADRA1D | |
| SCHEMBL29348961 | 0.84 | CRBN (0.37) | CRBNDDB1CD274PDCD1LG2ADRA1D | |
| SCHEMBL29348671 | 0.83 | CRBN (0.39) | CRBNDDB1CD274PDCD1LG2ADRA1D | |
| SCHEMBL29348622 | 0.78 | DDB1 (0.37) | CRBNDDB1CD274PDCD1LG2ADRA1D | |
| SCHEMBL31068339 | 0.78 | DDB1 (0.37) | CRBNDDB1CD274PDCD1LG2ADRA1D | |
| SCHEMBL31068263 | 0.76 | CRBN (0.35) | CRBNDDB1 | |
| SCHEMBL31068207 | 0.76 | DDB1 (0.39) | CRBNDDB1CD274PDCD1LG2ADRA1D | |
| SCHEMBL29348598 | 0.76 | DDB1 (0.39) | CRBNDDB1CD274PDCD1LG2ADRA1D | |
| SCHEMBL31068184 | 0.73 | DDB1 (0.39) | CRBNDDB1CD274PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |